As shown in Figure 6D, HCC patients with high levels of SOCS2 were resistant to combination therapy or small molecules such as nilotinib, TL‐1‐85, NG‐25, masitinib, axitinib, imatinib, and GNF‐2. This evidence concerns the gene SOCS2 and hepatocellular carcinoma.